Budesonide Inhaler Global Market Report 2025

The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.37 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to heightened awareness of inhalation therapies, growing adoption of corticosteroid treatments, rising air pollution levels leading to respiratory problems, increasing demand for minimally invasive drug delivery methods, and a stronger focus on home healthcare solutions.

The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $9.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in respiratory drug development, rising demand for personalized medicine in respiratory care, greater use of telemedicine and e-prescriptions, heightened awareness of early diagnosis and treatment, and a growing preference for combination inhaler therapies. Key trends during this period include advanced formulation techniques for improved drug delivery, innovations in smart inhalers with digital tracking, the integration of AI and IoT in respiratory health management, advancements in patient-centric drug designs, and the incorporation of mobile apps for adherence monitoring.

The growing incidence of respiratory disorders is expected to drive the expansion of the budesonide inhaler market in the coming years. Respiratory disorders, which affect the lungs and airways, can make breathing difficult and often lead to symptoms such as coughing, wheezing, and shortness of breath. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers help manage these disorders by delivering anti-inflammatory medication directly to the lungs, providing long-term control. Their compact design ensures ease of use and portability, reducing flare-ups and improving respiratory health. For example, according to the Australian Bureau of Statistics, the prevalence of chronic obstructive pulmonary disease (COPD) in Australia increased from 2.4% in 2021 to 2.5% in 2022. As a result, the growing prevalence of respiratory disorders is fueling the growth of the budesonide inhaler market.

Leading companies in the budesonide inhaler market are increasingly focused on developing innovative products, such as generic versions, to enhance affordability and broaden access to treatment for respiratory conditions. Generic inhalers are non-branded alternatives that contain the same active ingredients, dosage, and therapeutic effects as their branded counterparts, but typically at a lower price. For example, in July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery L.P., launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and COPD by reducing airway inflammation with budesonide, while formoterol relaxes the muscles around the airways, offering a more affordable option for patients.

In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Molex aims to establish a leading position in inhalation drug delivery by combining Phillips Medisize's manufacturing expertise with Vectura's specialization in inhalation devices and formulation development. This move will enhance Molex's ability to deliver innovative therapies for respiratory conditions. Vectura Group, based in the UK, is known for its work in developing inhalation drug delivery systems, including those used to administer budesonide.

Major players in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in budesonide inhaler report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the budesonide inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The budesonide inhaler is a respiratory device that delivers the corticosteroid medication budesonide directly to the lungs. It helps reduce airway inflammation, making breathing easier. The budesonide inhaler is typically prescribed for the long-term management of respiratory diseases.

The main types of products in the budesonide inhaler market include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. Metered-dose inhalers (MDIs) are handheld medical devices that deliver a precise amount of medication directly to the lungs in the form of a short burst of aerosolized medicine. The available dosage forms include aerosols, dry powder, suspension, and spray, each indicated for different conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The primary end-users of these products include hospitals, outpatient clinics, home care settings, and pharmacies.

The budesonide inhaler market research report is one of a series of new reports that provides budesonide inhaler market statistics, including budesonide inhaler industry global market size, regional shares, competitors with a budesonide inhaler market share, detailed budesonide inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. This budesonide inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.